Genetic variations in cytochrome P450 (CYP) 2D6 activity may have important clinical consequences for some drugs

Author：

ISSN： 1172-0360

Source： Drugs & Therapy Perspectives, Vol.26, Iss.5, 2010-05, pp. : 21-26

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Genetic Polymorphism in Cytochrome P450 2D6 (CYP2D6): Population Distribution of CYP2D6 Activity

By Neafsey Patricia

Journal of Toxicology and Environmental Health Part B: Critical Reviews, Vol. 12, Iss. 5-6, 2009-05 ,pp. : 334-361

Taylor & Francis Ltd

Access to resources Recommend Favorite

Reduced cytochrome P450 (CYP) 2D6 activity may contribute to an interaction between tramadol and warfarin

Reactions Weekly, Vol. 1, Iss. 1017, 2004-01 ,pp. : 4-4

Adis International

Access to resources Recommend Favorite

Effect of Genetic Polymorphisms in Cytochrome P450 (CYP) 2C9 and CYP2C8 on the Pharmacokinetics of Oral Antidiabetic Drugs: Clinical Relevance

By Kirchheiner Julia Roots Ivar Goldammer Mark Rosenkranz Bernd

Clinical Pharmacokinetics, Vol. 44, Iss. 12, 2005-01 ,pp. : 1209-1225

Adis International

Access to resources Recommend Favorite

An Evaluation of Ondansetron Binding Interactions with Human Cytochrome P450 Enzymes CYP3A4 and CYP2D6

Drug Metabolism Letters, Vol. 4, Iss. 1, 2010-01 ,pp. : 25-30

Bentham Science Publishers

Access to resources Recommend Favorite

Bupropion [amfebutamone] sustained-release (SR) is a potent inhibitor of cytochrome P450 (CYP)2D6

Reactions Weekly, Vol. 1, Iss. 1063, 2005-01 ,pp. : 5-5

Adis International

Access to resources Recommend Favorite